Spastic Paraplegia
9
5
5
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (9)
Extracorporeal Shockwave Therapy for Spasticity in People With Spinal Cord Injury
Exoskeleton-assisted Neurorehabilitation
Retrospective Study on the WalkOn AFO in Children or Teenagers With Neurological Pathologies
Correlation Between Clinical Assessment and Neurophysiological Assessment in Spinal Cord Injury
Natural History Study of Patients with HPDL Mutations
Turkish Lower-Extremity Motor Activity Log (LE-MAL)
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)
Cognitive Disorders in Hereditary Spastic Paraplegia Type 4
A Registered Cohort Study on Spastic Paraplegia